PURPOSE: Polymorphisms in the vitamin D receptor gene have been hypothesized to alter the risk of prostate cancer. However, studies investigating the associations between specific vitamin D receptor polymorphisms and prostate cancer risk have yielded inconsistent results. MATERIALS AND METHODS: We performed a meta-analysis of 26 studies evaluating the association between vitamin D receptor TaqI, poly(A), BsmI, ApaI, and/or FokI polymorphisms, and prostate cancer risk. RESULTS: The studies were heterogeneous in terms of study design, selection of cases and controls, and racial composition. Random effects models were used to estimate the pooled OR and 95% CI of each vitamin D receptor polymorphism under codominant, additive, dominant and recessive genetic models. Overall we did not find evidence to support an association between any of the vitamin D receptor polymorphisms and the risk of prostate cancer. For TaqI, which is the most studied vitamin D receptor polymorphism with 18 studies (total of 2,727 cases and 3,685 controls), the pooled OR was 1.00 (95% CI 0.85 to 1.18) for the Tt vs TT genotypes, 0.94 (95% CI 0.78 to 1.13) for the tt vs TT genotypes and 0.89 (95% CI 0.71 to 1.10) for the recessive model (tt vs Tt plus TT). ORs for the poly(A) microsatellite, BsmI, ApaI and FokI polymorphisms were similar. CONCLUSIONS: The results of this meta-analysis suggest that the vitamin D receptor TaqI, poly(A), BsmI, ApaI and FokI polymorphisms are not related to prostate cancer risk.
PURPOSE: Polymorphisms in the vitamin D receptor gene have been hypothesized to alter the risk of prostate cancer. However, studies investigating the associations between specific vitamin D receptor polymorphisms and prostate cancer risk have yielded inconsistent results. MATERIALS AND METHODS: We performed a meta-analysis of 26 studies evaluating the association between vitamin D receptor TaqI, poly(A), BsmI, ApaI, and/or FokI polymorphisms, and prostate cancer risk. RESULTS: The studies were heterogeneous in terms of study design, selection of cases and controls, and racial composition. Random effects models were used to estimate the pooled OR and 95% CI of each vitamin D receptor polymorphism under codominant, additive, dominant and recessive genetic models. Overall we did not find evidence to support an association between any of the vitamin D receptor polymorphisms and the risk of prostate cancer. For TaqI, which is the most studied vitamin D receptor polymorphism with 18 studies (total of 2,727 cases and 3,685 controls), the pooled OR was 1.00 (95% CI 0.85 to 1.18) for the Tt vs TT genotypes, 0.94 (95% CI 0.78 to 1.13) for the tt vs TT genotypes and 0.89 (95% CI 0.71 to 1.10) for the recessive model (tt vs Tt plus TT). ORs for the poly(A) microsatellite, BsmI, ApaI and FokI polymorphisms were similar. CONCLUSIONS: The results of this meta-analysis suggest that the vitamin D receptor TaqI, poly(A), BsmI, ApaI and FokI polymorphisms are not related to prostate cancer risk.
Authors: L J Ricks-Santi; V Apprey; T Mason; B Wilson; M Abbas; W Hernandez; S Hooker; M Doura; G Bonney; G Dunston; R Kittles; C Ahaghotu Journal: Prostate Cancer Prostatic Dis Date: 2012-07-17 Impact factor: 5.554
Authors: Emmanuel Y Jingwi; Muneer Abbas; Luisel Ricks-Santi; Danyelle Winchester; Desta Beyene; Agnes Day; Tammey J Naab; Olakunle O Kassim; Georgia M Dunston; Robert L Copeland; Yasmine M Kanaan Journal: Anticancer Res Date: 2015-03 Impact factor: 2.480
Authors: Juliette A Randerson-Moor; John C Taylor; Faye Elliott; Yu-Mei Chang; Samantha Beswick; Kairen Kukalizch; Paul Affleck; Susan Leake; Sue Haynes; Birute Karpavicius; Jerry Marsden; Edwina Gerry; Linda Bale; Chandra Bertram; Helen Field; Julian H Barth; Isabel Dos Santos Silva; Anthony Swerdlow; Peter A Kanetsky; Jennifer H Barrett; D Timothy Bishop; Julia A Newton Bishop Journal: Eur J Cancer Date: 2009-07-15 Impact factor: 9.162
Authors: Alison M Mondul; Irene M Shui; Kai Yu; Ruth C Travis; Victoria L Stevens; Daniele Campa; Frederick R Schumacher; Regina G Ziegler; H Bas Bueno-de-Mesquita; Sonja Berndt; E D Crawford; Susan M Gapstur; J Michael Gaziano; Edward Giovannucci; Christopher A Haiman; Brian E Henderson; David J Hunter; Mattias Johansson; Timothy J Key; Loïc Le Marchand; Sara Lindström; Marjorie L McCullough; Carmen Navarro; Kim Overvad; Domenico Palli; Mark Purdue; Meir J Stampfer; Stephanie J Weinstein; Walter C Willett; Meredith Yeager; Stephen J Chanock; Dimitrios Trichopoulos; Laurence N Kolonel; Peter Kraft; Demetrius Albanes Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-02-01 Impact factor: 4.254
Authors: Sarah K Holt; Erika M Kwon; Ulrike Peters; Elaine A Ostrander; Janet L Stanford Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05-19 Impact factor: 4.254
Authors: Desta A Beyene; Mohammad R Daremipouran; Victor Apprey; Tammey Naab; Olakunle O Kassim; Robert L Copeland; Yasmine M Kanaan Journal: Cancer Genomics Proteomics Date: 2020 Nov-Dec Impact factor: 4.069
Authors: Rebecca Suk Heist; Wei Zhou; Zhaoxi Wang; Geoffrey Liu; Donna Neuberg; Li Su; Kofi Asomaning; Bruce W Hollis; Thomas J Lynch; John C Wain; Edward Giovannucci; David C Christiani Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544